Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2024-11-22 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
第十届董事会临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at a board of directors meeting regarding an increase in capital investment to a subsidiary. It includes details about the meeting date, voting results, and references a related announcement published elsewhere. The content focuses on board decisions and capital allocation rather than full financial statements or detailed financial performance. The document length is short (527 characters), and it is an announcement of a board resolution rather than a full report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2024-11-22 Chinese
关于控股股东持有的公司股份可能被司法拍卖暨公司控制权或将发生变更的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the potential judicial auction of shares held by the company's controlling shareholder, which may lead to a change in control of the company. It details the auction process, risks, and legal context but does not contain financial statements, management discussion, or detailed financial data. The document is relatively short (2008 characters) and serves as a regulatory disclosure about a significant event affecting shareholding and control. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like M&A or Major Shareholding Notification, since it is about a judicial auction and potential control change but not a direct shareholding threshold crossing notification or merger filing.
2024-10-29 Chinese
关于聘任公司高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a senior management personnel (刘成良) at 启迪药业集团股份公司. It includes details about the appointment, the individual's background, and compliance with regulatory requirements. There is no financial data, no mention of financial results, no voting results, no legal proceedings, or other report types. The document is clearly about management changes, specifically the hiring of a senior executive. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on this announcement, confirming it is not a full report or other filing type.
2024-10-29 Chinese
关于向全资子公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's decision to increase capital investment in its wholly-owned subsidiary. It details the amount of capital increase, the subsidiaries involved, their financial data, and the purpose and impact of the investment. There is no indication that this is a full financial report, audit, or earnings release. The document is relatively short (3161 characters) and focuses on a capital increase transaction. Therefore, it fits the category of Capital/Financing Update (CAP).
2024-10-29 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the supervisory board's resolution approving the company's 2024 third quarter report. It includes details about the meeting date, attendance, and the supervisory board's audit opinion confirming the report's compliance and accuracy. The document itself does not contain the full third quarter financial report or substantive financial data, but rather the supervisory board's approval and audit opinion of that report. The document length is short (474 characters), and it serves as an official announcement of the approval of the interim/quarterly report rather than the report itself. Therefore, it fits best under the category of Regulatory Filings (RNS) as a formal compliance announcement rather than the full Interim/Quarterly Report (IR).
2024-10-29 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "启迪药业集团股份公司2024 年第三季度报告" which translates to "Qidi Pharmaceutical Group Co., Ltd. 2024 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial metrics for the third quarter of 2024. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the period ending September 30, 2024. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. The length of the document (12,591 characters) and the detailed financial content confirm it is a full quarterly report rather than a brief announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-10-29 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.